Skip to main content
SpringerLink
Log in

β-Blockers For Congestive Heart Failure

What is the Current Consensus?

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Despite the availability of angiotensin converting enzyme (ACE) inhibitors for patients with congestive heart failure (CHF), mortality and morbidity remains unacceptably high. CHF is thought to progress as a result of activation of endogenous neurohormonal systems which are activated by the initial myocardial injury. The 2 neurohormonal systems which seem to be important in CHF are the sympathetic nervous system (SNS), and the renin-angiotensin-aldosterone system (RAAS). While stimulation of the SNS has important circulatory support functions in the short term, long term activation appears to have deleterious effects on cardiac function and outcomes. The purpose of this article is to review the literature on the use of β-blockers in patients with CHF.

The published randomised clinical trials of β-blockers in patients with CHF have shown very promising effects on mortality and morbidity. Several systematic overviews of these trials also suggest beneficial effects on mortality, hospitalisation for CHF, need for transplant, and ejection fraction. The effect of β-blockers on exercise tolerance, New York Heart Association Function Class (NYHA-FC) and quality of life remain equivocal. The recent presentation of the results from several large-scale trials which were terminated early because of significant survival benefit, has removed any concern over the robustness of the mortality data. Available evidence suggests that a wide variety of patients with CHF, including the elderly, should be considered for β-blocker therapy. Caution is warranted in the initiation and titration of therapy, as symptoms of CHF may transiently worsen. Whether all β-blockers are equally efficacious remains unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971; 285: 1441–6

    Article  PubMed  CAS  Google Scholar 

  2. Yusuf S, Thom T, Abbot RD. Changes in hypertension and in congestive heart failure mortality. Hypertension 1989; 13Suppl. I: I–74 I–79

    Google Scholar 

  3. Kannel WB, Belanger AJ. Epidemiology in heart failure. Am Heart J 1991; 121: 951–7

    Article  PubMed  CAS  Google Scholar 

  4. Schocken DD, Arrieta MI, Leaverton PE. Prevalence in mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–6

    Article  PubMed  CAS  Google Scholar 

  5. Ho KKL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–15

    Article  PubMed  CAS  Google Scholar 

  6. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure: on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Am J Cardiol 1999; 83Suppl. 2A: 1A–38

    Article  Google Scholar 

  7. Johnstone DE, Abdulla A, Arnold JMO, et al. Diagnosis and management of heart failure. Can J Cardiol 1994; 10: 613–31

    PubMed  CAS  Google Scholar 

  8. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450–6

    Article  PubMed  CAS  Google Scholar 

  9. Yusuf S, Teo K. Inotropic agents increase mortality in patients with congestive heart failure. Circulation 1990; 82Suppl. III: III–673

    Google Scholar 

  10. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468–75

    Article  PubMed  CAS  Google Scholar 

  11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248–54

    Article  PubMed  CAS  Google Scholar 

  12. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure: Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997; 349: 747–52

    Article  PubMed  CAS  Google Scholar 

  13. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–23

    Article  PubMed  CAS  Google Scholar 

  14. Eichhorn EJ, Bristow MR. Medial therapy can improve the biological properties of the chronically failing heart. Circulation 1996; 94: 2285–96

    Article  PubMed  CAS  Google Scholar 

  15. Bristow M, Port JD. Beta adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl 1998; 47: 45–55

    PubMed  CAS  Google Scholar 

  16. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; II(8245): 490–2

    Article  Google Scholar 

  17. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471–5

    Article  PubMed  CAS  Google Scholar 

  18. Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536–46

    Article  PubMed  CAS  Google Scholar 

  19. Cucchini F, Compostella L, Papalia D, et al. Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. G Ital Cardiol 1988; 18: 835–42

    PubMed  CAS  Google Scholar 

  20. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223–9

    Article  PubMed  CAS  Google Scholar 

  21. Leung W-H, Lau C-P, Wong C-K, et al. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990; 119: 884–90

    Article  PubMed  CAS  Google Scholar 

  22. Pollock SG, Lystash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990; 66: 603–7

    Article  PubMed  CAS  Google Scholar 

  23. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426–41

    Article  PubMed  CAS  Google Scholar 

  24. Boutelant S, Lechat P, Komajda M, et al. Évaluation non invasive des effets cardiovasculaires du nébivolol chez l’insuffisant cardiaque [in French]. Arch Mal Coeur Vaiss 1992; 85: 863–70

    PubMed  CAS  Google Scholar 

  25. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992; 123: 103–10

    Article  PubMed  CAS  Google Scholar 

  26. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094–100

    Article  PubMed  CAS  Google Scholar 

  27. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310–20

    Article  PubMed  CAS  Google Scholar 

  28. Bristow MR, O’Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy: the bucindolol investigators. Circulation 1994; 89: 1632–42

    Article  PubMed  CAS  Google Scholar 

  29. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23: 943–50

    Article  PubMed  CAS  Google Scholar 

  30. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441–6

    Article  PubMed  CAS  Google Scholar 

  31. CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–73

    Article  Google Scholar 

  32. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13

    Article  Google Scholar 

  33. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–80

    Article  Google Scholar 

  34. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: the U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–55

    Article  PubMed  CAS  Google Scholar 

  35. Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997; 13: 1166–74

    PubMed  CAS  Google Scholar 

  36. Zarembski DG, Nolan Jr PE, Slack MK, et al. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 77: 1247–50

    Article  PubMed  CAS  Google Scholar 

  37. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27–34

    Article  PubMed  CAS  Google Scholar 

  38. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560–5

    Article  PubMed  CAS  Google Scholar 

  39. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184–91

    Article  PubMed  CAS  Google Scholar 

  40. Avezum A, Tsuyuki R, Pogue J, et al. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trials. Can J Cardiol 1998; 14: 1045–53

    PubMed  CAS  Google Scholar 

  41. Pogue J, Yusuf S. Overcoming the limitations of current metaanalysis of randomized controlled trials. Lancet 1998; 351: 47–52

    Article  PubMed  CAS  Google Scholar 

  42. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71

    Article  PubMed  CAS  Google Scholar 

  43. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794–8

    Article  PubMed  CAS  Google Scholar 

  44. Jansen RWMM, Gurwitz JH. Controversies surrounding the use of beta-blockers in older patients with cardiovascular disease. Drugs Aging 1994; 4: 175–83

    Article  PubMed  CAS  Google Scholar 

  45. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992; 268: 1417–22

    Article  PubMed  CAS  Google Scholar 

  46. McAlister FA, Taylor L, Teo KK, et al. The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? J Am Geriatr Soc 1999; 47: 811–18

    PubMed  CAS  Google Scholar 

  47. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97

    Article  PubMed  CAS  Google Scholar 

  48. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115–21

    Article  PubMed  CAS  Google Scholar 

  49. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998; 280: 623–9

    Article  PubMed  CAS  Google Scholar 

  50. Bright RA, Everitt DE. Beta-blockers and depression: evidence against an association. JAMA 1992; 267: 1783–7

    Article  PubMed  CAS  Google Scholar 

  51. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med 1989; 149: 514–25

    Article  PubMed  CAS  Google Scholar 

  52. Dahlof C, Dimenas E, Kendall M, et al. Quality of life in cardiovascular diseases: emphasis on beta-blocker treatment. Circulation 1991; 84Suppl. VI: 108–18

    Google Scholar 

  53. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769–76

    Article  PubMed  CAS  Google Scholar 

  54. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Tsuyuki is supported by the University Hospital Foundation. Dr McAlister is supported by the Medical Research Council of Canada. Dr Teo is supported by the Alberta Heritage Foundation for Medical Research.

Author information

Authors and Affiliations

  1. Divisions of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

    Ross T. Tsuyuki &  Koon K. Teo

  2. Internal Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

    Finlay A. McAlister

Authors
  1. Ross T. Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Finlay A. McAlister
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koon K. Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koon K. Teo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsuyuki, R.T., McAlister, F.A. & Teo, K.K. β-Blockers For Congestive Heart Failure. Drugs Aging 16, 1–7 (2000). https://doi.org/10.2165/00002512-200016010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200016010-00001

Keywords

Search

Navigation